Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 5
2014 3
2015 3
2016 5
2017 6
2018 15
2019 11
2020 5
2021 12
2022 17
2023 31
2024 21
2025 16
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.
Patel M, Feng W, Mckay NS, Millar PR, Liu M, Yang C, Cetin A, Johnson M, Budde J, Western D, Marsh TW, Saliu IO, Gordon BA, Guerra JJL, Morris JC, Bateman RJ, McDade E, Holtzman DM, Ryan NS, Benzinger TLS, Renton AE, Goate AM, Ibanez L, Sung YJ, Zhao G, Cruchaga C, Pottier C; Dominantly Inherited Alzheimer Network. Patel M, et al. Lancet Neurol. 2026 Jun;25(6):581-590. doi: 10.1016/S1474-4422(26)00123-7. Lancet Neurol. 2026. PMID: 42127933 Free PMC article.
METHODS: In this genome-wide association study, we analysed data from participants in three study cohorts (the Knight Alzheimer Disease Research Center [Knight-ADRC], the Dominantly Inherited Alzheimer Network [DIAN] observational study, and the Alzhei …
METHODS: In this genome-wide association study, we analysed data from participants in three study cohorts (the Knight Alzheimer Disease Rese …
Molecular and Structural Characterization Reveals Divergent Extracellular Vesicle Profiles Between Wild Type and Alzheimer's Disease Cerebrocortical Organoids.
Balistreri A, Turner N, Compher J, Almaraz M, Prabhavalkar A, Chittal S, Labra SR, Ezekiel K, Baal C, Kwong CC, Ghatak S, Schäfer JH, Vanderpool K, Spencer K, Yates JR 3rd, Nolan JP, Henderson S, Lipton SA, Kelly JW. Balistreri A, et al. bioRxiv [Preprint]. 2026 May 14:2026.05.13.724352. doi: 10.64898/2026.05.13.724352. bioRxiv. 2026. PMID: 42182203 Free PMC article. Preprint.
After a 1-week co-culture of AD organoids with WT organoids, there is evidence of endosomal membrane transfer between the isogenic cultures with an increase in amyloid-beta peptides in the WT organoids. These observations support the notion that non-cell-autonomous …
After a 1-week co-culture of AD organoids with WT organoids, there is evidence of endosomal membrane transfer between the isogenic cultures …
Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer's Disease.
Lin W, Beric A, Wisch JK, Baker B, Jerome G, Minton M, Preminger S, Stauber J, Schindler SE, Dage JL, Allegri R, Aguillon D, Benzinger T, Chhatwal J, Daniels A, Day GS, Devenney E, Fox NC, Goate A, Gordon BA, Barthélemy NR, Hassenstab J, Huey E, Ikeuchi T, Jayadev S, Jucker M, Ishiguro T, Lee JH, Levey AI, Levin J, Morris JC, Perrin RJ, Renton A, Roh JH, Xiong C, Bateman RJ, Ances BM, Cruchaga C, Karch CM, Supnet-Bell C, Llibre-Guerra J, McDade E; Dominantly Inherited Alzheimer Network; Ibanez L. Lin W, et al. medRxiv [Preprint]. 2026 Apr 1:2026.03.31.26349851. doi: 10.64898/2026.03.31.26349851. medRxiv. 2026. PMID: 41959774 Free PMC article. Preprint.
Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer's disease.
Choo IH, Park H, Gordon BA, Bateman RJ; Dominantly Inherited Alzheimer Network. Choo IH, et al. J Prev Alzheimers Dis. 2026 Apr;13(4):100513. doi: 10.1016/j.tjpad.2026.100513. Epub 2026 Feb 27. J Prev Alzheimers Dis. 2026. PMID: 41763013 Free PMC article.
OBJECTIVE: To investigate longitudinal subcortical structural changes in autosomal dominant Alzheimer's disease in relation to multiple PET and fluid biomarkers. DESIGN: Dominantly Inherited Alzheimer's Network (DIAN) Observational study SETTING …
OBJECTIVE: To investigate longitudinal subcortical structural changes in autosomal dominant Alzheimer's disease in relation to multiple PET …
Critical and non-critical connections not differently associated with either Alzheimer's disease or vascular pathologies.
Vlegels N, de Brito Robalo BM, de Luca A, van der Flier WM; Dominantly Inherited Alzheimer Network (DIAN); Bateman R, Benzinger TLS, Cruchaga C, Cash DM, Mori H, Yakushev I, Duering M, Finsterwalder S, Gesierich B, Kopczak A, Reijmer YD, Biessels GJ. Vlegels N, et al. medRxiv [Preprint]. 2026 Feb 4:2026.02.03.26345446. doi: 10.64898/2026.02.03.26345446. medRxiv. 2026. PMID: 41674644 Free PMC article. Preprint.
For patients with CADASIL (n=59), Mixed pathology (n=57) and autosomal dominant AD (ADAD; n=50) we reconstructed WM networks based on diffusion tensor imaging and subsequently defined critical and non-critical connections. Associations between AD markers (CSF Abeta(42), p- …
For patients with CADASIL (n=59), Mixed pathology (n=57) and autosomal dominant AD (ADAD; n=50) we reconstructed WM networks based on diffus …
Plasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease.
Schultz SA, Rao Y, Liu L, Ostaszewski B, Anderson AK, Yau WW, Shirzadi Z, Gordon BA, Hassenstab J, Morris JC, Perrin RJ, Allegri RF, Barthélemy NR, Fox N, Day GS, Jucker M, Levey AI, Levin J, Mori H, Salloway S, Schofield P, McDade E, Sperling RA, Bateman RJ, Selkoe DJ, Chhatwal JP; and the Dominantly Inherited Alzheimer's Network. Schultz SA, et al. Alzheimers Dement. 2026 Jan;22(1):e71049. doi: 10.1002/alz.71049. Alzheimers Dement. 2026. PMID: 41505233 Free PMC article.
NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of beta-amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasm …
NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of beta-am …
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.
Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, Rothberg DM, Kouri N, Hinkle KM, Roemer SF, Johnson DR, Burkett BJ, Lowe VJ, Petersen RC, Dickson DW, Reichard RR, Nguyen AT, Graff-Radford J, Knopman DS, Graff-Radford NR, Murray ME. Boon BDC, et al. Lancet Neurol. 2025 Nov;24(11):931-944. doi: 10.1016/S1474-4422(25)00313-8. Lancet Neurol. 2025. PMID: 41109234 Free PMC article. Clinical Trial.
BACKGROUND: Understanding the neuropathological effects of amyloid beta (Abeta)-targeting therapies and amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease is critical for optimising treatment efficacy and patient outcomes. Comparing Abeta …
BACKGROUND: Understanding the neuropathological effects of amyloid beta (Abeta)-targeting therapies and amyloid-related …
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals.
Cogswell PM, Wiste HJ, Therneau TM, Griswold ME, Mattsson-Carlgren N, Palmqvist S, Binette AP, Stomrud E, Bateman RJ, Barthelemy N, Braunstein JB, West T, Verghese PB, Machulda MM, Graff-Radford J, Algeciras-Schimnich A, Lowe VJ, Schwarz CG, Senjem ML, Gunter JL, Knopman DS, Vemuri P, Petersen RC, Hansson O, Jack CR Jr. Cogswell PM, et al. Alzheimers Dement. 2025 Sep;21(9):e70625. doi: 10.1002/alz.70625. Alzheimers Dement. 2025. PMID: 40883967 Free PMC article.
Amyloid PET and percent phosphorylated to non-phosphorylated tau217 (%p-tau217) were strong predictors of progression to MCI in both cohorts: hazard ratios of 1.49 and 1.23 in the MCSA and 1.72 and 1.65 in BioFINDER, respectively. Amyloid beta 42/40 was a significan …
Amyloid PET and percent phosphorylated to non-phosphorylated tau217 (%p-tau217) were strong predictors of progression to MCI in both cohorts …
144 results